Cargando…

Rad5 dysregulation drives hyperactive recombination at replication forks resulting in cisplatin sensitivity and genome instability

The postreplication repair gene, HLTF, is often amplified and overexpressed in cancer. Here we model HLTF dysregulation through the functionally conserved Saccharomyces cerevisiae ortholog, RAD5. Genetic interaction profiling and landscape enrichment analysis of RAD5 overexpression (RAD5(OE)) reveal...

Descripción completa

Detalles Bibliográficos
Autores principales: Bryant, Eric E, Šunjevarić, Ivana, Berchowitz, Luke, Rothstein, Rodney, Reid, Robert J D
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6753471/
https://www.ncbi.nlm.nih.gov/pubmed/31350889
http://dx.doi.org/10.1093/nar/gkz631
Descripción
Sumario:The postreplication repair gene, HLTF, is often amplified and overexpressed in cancer. Here we model HLTF dysregulation through the functionally conserved Saccharomyces cerevisiae ortholog, RAD5. Genetic interaction profiling and landscape enrichment analysis of RAD5 overexpression (RAD5(OE)) reveals requirements for genes involved in recombination, crossover resolution, and DNA replication. While RAD5(OE) and rad5Δ both cause cisplatin sensitivity and share many genetic interactions, RAD5(OE) specifically requires crossover resolving genes and drives recombination in a region of repetitive DNA. Remarkably, RAD5(OE) induced recombination does not require other post-replication repair pathway members, or the PCNA modification sites involved in regulation of this pathway. Instead, the RAD5(OE) phenotype depends on a conserved domain necessary for binding 3′ DNA ends. Analysis of DNA replication intermediates supports a model in which dysregulated Rad5 causes aberrant template switching at replication forks. The direct effect of Rad5 on replication forks in vivo, increased recombination, and cisplatin sensitivity predicts similar consequences for dysregulated HLTF in cancer.